Increased Frequency of IDH1/2 Mutations in Extramedullary Acute Myeloid Leukemia

ConclusionOverall, EM-AML patients had targetable mutations (i.e. IDH1/IDH2/FLT3) in 40% of cases with an increased frequency of IDH1/2 mutations (31%) in comparison to the general AML population. IDH mutant EM-AML patients achieved clinical benefit to specific inhibitors. These data support mutational analysis of EM-AML patients in order to personalize therapeutic options for our patients.Figure 1.DisclosuresBhagat: Genoptix: Employment. Watts: Takeda: Research Funding; Jazz Pharma: Consultancy, Speakers Bureau. Sweet: Novartis: Consultancy, Honoraria, Speakers Bureau; Novartis: Consultancy, Honoraria, Speakers Bureau; Jazz: Speakers Bureau; Celgene: Honoraria, Speakers Bureau; Jazz: Speakers Bureau; BMS: Honoraria; Astellas: Consultancy; Celgene: Honoraria, Speakers Bureau; Astellas: Consultancy; Agios: Consultancy; Agios: Consultancy; Phizer: Consultancy; Phizer: Consultancy; BMS: Honoraria. Komrokji: Celgene: Honoraria, Research Funding; Novartis: Honoraria, Speakers Bureau; Celgene: Honoraria, Research Funding; Novartis: Honoraria, Speakers Bureau; Novartis: Honoraria, Speakers Bureau; Novartis: Honoraria, Speakers Bureau. Sallman: Celgene: Research Funding, Speakers Bureau.

Source: Blood - November 21, 2018 Category: Hematology Authors: Knepper, T. C., Deutsch, Y. E., Bhagat, C. K., Watts, J. M., Bradley, T. J., Samra, W., Hussaini, M. O., Sweet, K. L., Talati, C., Padron, E., Komrokji, R. S., Lancet, J. E., Sallman, D. A. Tags: 617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Poster I Source Type: research